Am J Cardiovasc Drugs. 2010;10(4):271-9. doi: 10.2165/11533460-000000000-00000.
Genzyme Corporation and Isis Pharmaceuticals have a worldwide licensing and collaboration agreement for the development of subcutaneous mipomersen (ISIS 147764; ISIS 301012; ISIS301012; mipomersen-sodium). Mipomersen, an oligonucleotide antisense inhibitor directed against apolipoprotein B-100 (apoB-100) mRNA, is in phase III clinical evaluation for the treatment of familial hypercholesterolemia, a form of type IIa hyperlipoproteinemia, and hypercholesterolemia in patients with severely high cholesterol levels or at high risk for coronary heart disease in the US, European Union, Brazil, Canada, South Africa, and South East Asia. This review discusses the development history and scientific profile of this new compound.
健赞公司和艾西斯制药公司签订了一份全球许可和合作协议，共同开发皮下注射米泊美生（ISIS147764；ISIS301012；ISIS301012；米泊美生钠）。米泊美生是一种针对载脂蛋白 B-100（apoB-100）mRNA 的寡核苷酸反义抑制剂，目前正在进行 III 期临床试验，用于治疗家族性高胆固醇血症，这是 IIa 型高脂蛋白血症的一种形式，以及美国、欧盟、巴西、加拿大、南非和东南亚严重高胆固醇水平或冠心病高危患者的高胆固醇血症。这篇综述讨论了这种新型化合物的开发历史和科学概况。
